Cite
HARVARD Citation
Naismith, R. et al. (2020). Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Multiple sclerosis. pp. 1729-1739. [Online].